GlassScriptPhysician profile
Iyad Rashdan
NPI 1811955123
$2,853.85
in general payments reported to CMS, 2019-2025
27 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $1,029 · 2021: $331 · 2022: $331 · 2023: $340 · 2024: $157 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $898.77 | 2020-2025 | Jot Dx, Xience Sierra, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $442.39 | 2021-2025 | Lifevest |
| Welch Allyn | $300.71 | 2020 | |
| Sanofi-Aventis U.S. LLC | $163.97 | 2019-2023 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Pfizer INC. | $100.60 | 2019-2025 | |
| Medtronic, INC. | $93.99 | 2022-2025 | Symplicity G3, Corevalve Evolut R |
| Biotronik INC. | $92.98 | 2019-2022 | |
| Boston Scientific Corporation | $85.44 | 2019-2023 | Accolade Sr |
| E.R. Squibb & Sons, L.L.C. | $69.97 | 2019-2022 | |
| Heartflow, INC. | $61.33 | 2019-2020 | |
| Cvrx, INC. | $61.13 | 2023-2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $51.88 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $40.50 | 2019 | |
| Amgen INC. | $32.40 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $31.82 | 2021-2022 | |
| Amarin Pharma, INC. | $29.56 | 2020-2021 | |
| Medtronic Vascular, INC. | $29.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $18.48 | 2021 | |
| Lundbeck LLC | $18.39 | 2020 | |
| Cook Medical LLC | $18.15 | 2022 | |
| G Medical Diagnostic Services, INC. | $14.95 | 2022 | |
| Althera Pharmaceuticals LLC | $13.47 | 2021 | |
| Edwards Lifesciences Corporation | $12.83 | 2019 | |
| Gilead Sciences, INC. | $12.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iyad Rashdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.